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Abstract
AIM
To determine the distribution of anthropometric 
parameter (AP)-z -scores and characterize associations 
between medications/serum biomarkers and AP-z -
scores in pediatric Crohn’s disease (CD).
METHODS
CD patients [< chronological age (CA) 21 years] 
were enrolled in a cross-sectional study. Descriptive 
statistics were generated for participants’ demographic 
characteristics and key variables of interest. Paired 
t -tests were used to compare AP-z -scores calculated 
based on CA (CA z -scores) and bone age (BA) (BA 
z -scores) for interpretation of AP’s. Linear regression 
was uti l ized to examine associations between 
medications and serum biomarkers with AP-z -scores 
calculated based on CA (n  = 82) and BA (n  = 49). 
We reported regression coefficients as well as their 
corresponding p-values and 95% confidence intervals.
RESULTS
Mean CA at the time of the study visit was 15.3 ± 3.5 
(SD; range = 4.8-20.7) years. Mean triceps skinfold (P  
= 0.039), subscapular skinfold (P  = 0.002) and mid-
arm circumference (MAC) (P  = 0.001) BA z -scores were 
higher than corresponding CA z -scores. Medications 
were positively associated with subscapular skinfold 
[adalimumab (P  = 0.018) and methotrexate (P  = 
0.027)] and BMI CA z -scores [adalimumab (P  = 
0.029)]. Azathioprine/6-mercaptopurine were negatively 
associated with MAC (P  = 0.045), subscapular skinfold 
(P  = 0.014), weight (P  = 0.002) and BMI (P  = 0.013) 
CA z -scores. ESR, CRP, and WBC count were negatively 
associated, while albumin and IGF-1 BA z -scores 
were positively associated, with specific AP z -scores 
(P  < 0.05). Mean height CA z -scores were higher in 
females, not males, treated with infliximab (P = 0.038). 
Hemoglobin (P  = 0.018) was positively associated, 
while platelets (P  = 0.005), ESR (P  = 0.003) and CRP 
(P  = 0.039) were negatively associated with height CA 
z -scores in males, not females. 
CONCLUSION
Our results suggest poor efficacy of thiopurines and 
a possible sex difference in statural growth response 
to infliximab in pediatric CD. Prospective longitudinal 
studies are required.
Key words: Inflammatory bowel disease; Azathioprine/
6-mercaptopurine; Biologics; Nutrition
© The Author(s) 2018. Published by Baishideng Publishing 
Group Inc. All rights reserved.
Core tip: Azathioprine/6-mercaptopurine were negatively 
associated with specific anthropometric parameters, 
suggesting a possible negative effect vs  poor efficacy of 
thiopurines in pediatric Crohn’s disease (CD). Infliximab 
was positively associated with standardized height in 
females only, suggesting a possible sex difference in 
response to infliximab from the standpoint of statural 
growth in pediatric CD. Specific serum biomarkers were 
associated with standardized height in males only, 
supporting that inflammation has a more detrimental 
effect on statural growth in males with pediatric CD.
Gupta N, Lustig RH, Chao C, Vittinghoff E, Andrews H, Leu 
CS. Thiopurines are negatively associated with anthropometric 
parameters in pediatric Crohn’s disease. World J Gastroenterol 
2018; 24(18): 2036-2046  Available from: URL: http://www.
wjgnet.com/1007-9327/full/v24/i18/2036.htm  DOI: http://
dx.doi.org/10.3748/wjg.v24.i18.2036
INTRODUCTION
Several studies document alterations in anthropometric 
parameters in pediatric Crohn’s disease (CD) such as 
lean mass deficits[1-5], reductions in fat free mass[6,7] , 
fat mass deficits[3,5,7], low body mass index (BMI)[1-3,5-8], 
high BMI[7,8], and low height[1-3,5,9,10]. Similar to impaired 
statural growth (height velocity), a dynamic marker of 
disease status, body composition deficits may reflect 
poorly controlled disease despite the absence of overt 
clinical intestinal symptoms. 
Delayed bone age (BA) is common in pediatric 
CD[10-16]. BA assessed by left hand X-ray is regarded as a 
valid measure of skeletal maturity[13-14,17-19]. Determination 
of BA allows clinically meaningful interpretation of growth 
in the context of skeletal maturity in pediatric CD[11]. 
Mean height, weight and BMI z-scores calculated based 
on BA (BA z-scores) are higher than corresponding 
z-scores calculated based on chronological age (CA) (CA 
z-scores) in pediatric CD[11]. 
The impact of accounting for BA in the interpretation 
of body composition is unclear. Accurate interpretation 
of body composition is important since it reflects nu-
tritional[4] and disease status. Not only is nutritional status 
an important determinant of pubertal development and 
growth velocity[20], it is a prognostic factor for disease 
course[21-28]. Several factors affect nutritional status, 
including inflammation, medications, nutrient intake, and 
hormones[4,29,30]. The association between medications 
and serum inflammatory and hormonal biomarkers with 
anthropometric measurements is not well delineated in 
pediatric CD, particularly after adjusting for maturational 
status (BA).
Nutritional status is an important factor to consider 
when making therapeutic decisions given its association 
with poor outcomes[21-28]. Yet, the impact of treatments 
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on anthropometric measurements is poorly defined 
and has not received sufficient attention[31]. While there 
are well-documented sex differences in risk for statural 
growth impairment[9-10,14,21,32-35], sex differences in 
nutritional status require further study. Data regarding 
the relationship between medications and serum 
biomarkers with anthropometric parameters by sex, an 
important biological variable, are lacking.
Here we assessed body composition by skinfold 
measurements in pediatric CD. Our aims were to (1) 
determine the distribution of anthropometric parameters 
based on CA (CA z-scores) and BA (BA z-scores); and 
(2) characterize the associations between medications 
and serum biomarkers with anthropometric parameter 
z-scores in pediatric CD.
MATERIALS AND METHODS
Pediatric CD patients < CA 21 years enrolled in this 
cross-sectional study at University of California, San 
Francisco (UCSF) between January 2007 and July 2009 
as previously described[10-11,36]. We excluded patients 
who received growth hormone ever or corticosteroids 
within 2 mo prior to study participation since more 
recent use would suppress the somatotropic axis and 
interfere with accurate assessment of insulin-like growth 
factor-1 (IGF-1) levels. Eighty-two patients completed 
the study. 
Mid-arm circumference measurements and skinfold 
thickness measurements were collected to the nearest 0.1 
mm from the non-dominant side of the body in triplicate 
and averaged. A measuring tape was used for mid-arm 
circumference measurements and Lange skinfold calipers 
were used for skinfold thickness measurements. The mid-
arm circumference measurement was obtained at the 
mid-point between the olecranon process and acromion. 
The triceps skinfold measurement was obtained at 
the mid-point of the upper arm, halfway between the 
acromion and the olecranon. The subscapular skinfold 
was measured at a 45° angle just below the inferior 
angle of the scapula. One of two registered dietitians 
obtained the measurements. Both were trained using 
standardized NHANES methodologies with established 
inter-rater reliability[37]. Weight and height were measured 
using a digital scale (Scale-Tronix, White Plains, NY, 
United States) to the nearest 0.1 kg and stadiometer 
(Proscale, Accurate Technology, Inc., Cincinnati, OH, 
United States) to the nearest 0.1 cm, respectively. Body 
mass index (BMI) was calculated as the weight in kg 
divided by the square of the height in meters. Self-Tanner 
staging was performed[38]. Left hand x-rays obtained for 
BA were blindly interpreted by RL using the standards of 
Greulich and Pyle[17].
Medications of interest included adalimumab, 5-am-
inosalicylates, antibiotics, azathioprine/6-mercaptopurine 
(thiopurines), infliximab, and methotrexate. 
We classified disease location as esophagus or 
stomach; small bowel, no colon; small bowel and colon; 
colon, no small bowel; perianal.
A lab draw was performed to measure serum IGF-1, 
insulin-like growth factor binding protein 3 (IGFBP-3), 
testosterone, estradiol, luteinizing hormone (LH), follicle 
stimulating hormone (FSH), albumin, alkaline phos-
phatase, C-reactive protein (CRP), erythrocyte sedimen-
tation rate (ESR), hemoglobin, platelets, and white 
blood cell (WBC) count. Tubes for serum hormone levels 
and routine clinical labs were processed by Esoterix 
Endocrinology (Calabasas Hills, CA, United States) and 
UCSF clinical lab, respectively. Clinical information was 
collected. 
Statistical analysis
We calculated CA z-scores for IGF-1, IGFBP-3, estradiol, 
testosterone, FSH, LH, mid-arm circumference, triceps 
skinfold, subscapular skinfold, weight, height, and BMI 
using reference values based in part on CA. Because 
pubertal growth acceleration correlates more closely 
with BA than CA[39], we also calculated BA z-scores for 
all 17 females ≤ CA 15 and 32 males ≤ CA 17 years, 
as epiphyses close at BA 15 in females and 17 years 
in males. We excluded all females > CA 15 and males 
> CA 17 years from BA analyses because sufficient 
reference data on variability of BA beyond these CA 
thresholds are not available. We transformed mid-arm 
circumference, triceps skinfold, subscapular skinfold, 
weight, height, and BMI measurements to z-scores[40-45]. 
Means and standard deviations (SDs) provided by 
Esoterix Endocrinology were used to calculate IGF-1 
and IGFBP-3 z-scores. The mean and the upper and 
lower bounds of the normal ranges (specific to sex, age, 
and Tanner stage), accounting for asymmetry about 
the mean if present, were used to compute SDs for 
gonadotropins and sex hormones. Low and high z-scores 
are defined as z-scores < -2.0 and > 2.0, respectively.
Descriptive statistics were generated for participants’ 
demographic characteristics and key variables of 
interest. Paired t-tests were used to compare CA z-scores 
and BA z-scores for interpretation of anthropometric 
parameters. We employed linear regression to assess 
the associations between predictors (medications and 
serum biomarkers) and outcomes (anthropometric 
parameter CA z-scores and BA z-scores). For outcomes 
based on CA z-scores (n = 82), we also conducted 
analyses including CA at study visit, sex, CRP, albumin, 
ESR, and hemoglobin in the model to adjust for 
potential confounding. We conducted additional analyses 
adjusting for disease activity indices, disease duration, 
stricturing disease and penetrating disease in these 
models. We analyzed height CA z-scores separately by 
sex because of well-established sex differences in risk 
for statural growth impairment[9-10,14,21,32-35]. We reported 
regression coefficients as well as their corresponding 
p-values and 95% confidence intervals (CI); p-values 
< 0.05 were considered as statistically significant. Data 
were analyzed using IBM SPSS Statistics 23.
Ethical considerations
We obtained Institutional Review Board Approval for the 
study protocol. Informed consent/assent were obtained 
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Of the 4 patients on adalimumab, 1 (25%) was on 
monotherapy, 1 (25%) was on combination therapy 
with thiopurines, 2 (50%) were on combination therapy 
with methotrexate.
Anthropometric parameters
Anthropometric parameters are summarized in Table 2.
Bone age vs chronological age for the interpretation of 
anthropometric parameters
For the 49 patients qualifying for BA analyses, mean 
BA (12.2 ± 2.9 years) was significantly lower than 
mean CA (13.1 ± 2.6 years) (p < 0.0001)[10]. Mid-
arm circumference (0.35 units, 95%CI: 0.14-0.55; p 
= 0.001), subscapular skinfold (0.10 units, 95%CI: 
0.04-0.16; p = 0.002), and triceps skinfold (0.05 units, 
95%CI: 0.003-0.11; p = 0.039) BA z-scores were 
systematically higher than corresponding CA z-scores. 
Medications, serum biomarkers, and anthropometric 
parameters
Tables 3 and 4 show the unadjusted and adjusted 
associations, respectively, between medication treatment, 
serum biomarkers and anthropometric parameter CA 
z-scores (height CA z-scores presented separately) 
that achieved statistical significance. Infliximab was 
not statistically significantly associated with mid-arm 
circumference, triceps skinfold, subscapular skinfold, 
weight or BMI CA z-scores (data not shown). Results 
did not change when disease activity indices, disease 
duration, stricturing disease or penetrating disease were 
included in the adjusted models.
Table 5 shows the unadjusted associations between 
serum biomarkers and anthropometric parameter BA 
z-scores (height BA z-scores presented separately). 
Medication treatments were not statistically significantly 
associated with anthropometric parameter BA z-scores.
Table 6 shows the unadjusted associations between 
medications, serum biomarkers and height CA z-scores 
by sex. 
Table 7 shows the unadjusted association between 
serum biomarkers and height BA z-scores. Medications 
were not statistically significantly associated with height 
BA z-scores.
DISCUSSION
In our prospective, cross-sectional study, azathioprine/6-
mercaptopurine were negatively associated with lean 
tissue mass (mid-arm circumference CA z-scores) and 
fat store (subscapular CA z-scores) measurements, and 
weight CA z-scores and BMI CA z-scores in pediatric 
CD. We previously reported thiopurine treatment 
was associated with lower standardized BA results[11]. 
From a mechanistic perspective, it is unlikely these 
associations represents a direct negative impact of 
thiopurines on skeletal maturation or anthropometric 
parameters. When examining the association between 
from parents/patients.
RESULTS
Participant characteristics
82 patients completed the study; 35 (43%) were 
female[10]. Mean CA at the time of the study visit was 
15.3 ± 3.5 (SD; range = 4.8-20.7) years[10]. Mean 
CA at the time of inflammatory bowel disease (IBD) 
diagnosis was 12.1 ± 3.8 (0.5-17.9) years. Mean 
time since IBD diagnosis was 3.4 ± 2.8 (0.01-12.0) 
years. Race/ethnicity, Tanner stage, disease location, 
and medications are summarized in Table 1. History of 
corticosteroid use did not differ by sex[10].
Monotherapy vs combination therapy
Of the 44 patients on azathioprine/6-mercaptopurine, 
33 (75%) were on thiopurine monotherapy, 10 (23%) 
were on combination therapy with infliximab and 1 (2%) 
was on combination therapy with adalimumab.
Of the 7 patients on methotrexate, 3 (43%) were on 
monotherapy, 2 (28.5%) were on combination therapy 
with infliximab and 2 (28.5%) were on combination 
therapy with adalimumab.
Of the 20 patients on infliximab, 8 (40%) were on 
monotherapy, 10 (50%) were on combination therapy 
with thiopurines and 2 (10%) were on combination 
therapy with methotrexate.
Table 1  Demographics, Tanner stage, disease location, and 
medications
Item n  (%)
Race
   Asian 12 (14.6)
     East Asian 6
     South Asian 6
   Black/African American 1 (1.2)
   Other 4 (4.9)
   White 65 (79.3)
Ethnicity
   Hispanic or Latino 7 (8.5)
   Not Hispanic or Latino 75 (91.5)
Tanner stage
   1 8 (9.8)
   2 15 (18.3)
   3 16 (19.5)
   4 24 (29.3)
   5 19 (23.2)
Disease location
   Esophagus or stomach 9 (11)
   Small bowel, no colon 12 (14.6)
   Colon, no small bowel 17 (20.7)
   Small bowel and colon 53 (64.6)
   Perianal disease 49 (59.8)
Medication
   Adalimumab 4 (4.9)
   5-Aminosalicylates 50 (61.0)
   Antibiotics 14 (17.1)
   Azathioprine/6-Mercaptopurine 44 (53.7)
   Infliximab 20 (24.4)
   Methotrexate 7 (8.5)
   Steroids ever 55 (67.1)
Gupta N et al . Anthropometrics in pediatric CD
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azathioprine/6-mercaptopurine and BA z-scores for these 
specific anthropometric parameters, the direction of the 
association remained negative between thiopurines and 
subscapular skinfold BA z-scores (though did not achieve 
statistical significance due to smaller sample size (n 
= 49 for BA analyses vs n = 82 for CA analyses). This 
continued negative association between thiopurines and 
subscapular skinfold BA z-scores in combination with 
our previously reported finding of a negative association 
between thiopurines and standardized BA results[11] 
calls into question the efficacy of thiopurines for treating 
pediatric CD. Our findings highlight the importance of 
considering BA in the interpretation of anthropometric 
parameters because its inclusion clarifies the relationship 
between medications and these outcomes. 
Previously published data on the impact of thiop-
urines on anthropometry for comparison to our findings 
are limited, but also raise concerns about the efficacy 
of these medications. Csontos et al[31] reported no 
statistically significant difference in the change in 
fat free mass index, skeletal muscle index, or body 
fat mass index in adult IBD patients on vs not on 
azathioprine during initiation of biologic therapy. In newly 
diagnosed CD children randomized to treatment with 
6-mercaptopurine plus steroids vs placebo plus steroids, 
Markowitz et al[46] did not detect a difference in statural 
growth. 
Regarding a possible negative impact of utilizing thiop-
urines, in a pediatric IBD cohort, Hyams et al[47] reported 
thiopurine exposure is an important preceding event 
for the development of malignancy or hemophagocytic 
lymphohistiocytosis. Our data identify another negative 
signal associated with thiopurines, given the constellation 
of findings of statistically significant negative associations 
between azathioprine/6-mercaptopurine and mid-arm 
circumference, subscapular skinfold, weight and BMI 
CA z-scores and persistent negative association with 
subscapular skinfold BA z-scores (though did not achieve 
statistical significance due to smaller sample size available 
for BA analyses), in combination with our previously 
reported finding of a statistically significant association 
with lower standardized BA results[11]. Prospective 
longitudinal study is required to examine the longitudinal 
pattern of these associations and to investigate whether 
Table 2  Summary of anthropometric parameters
Variable (n ) Mean ± SD Range Percent with z -scores > 2 (%) Percent with z -scores < -2 (%)
Mid-arm circumference-CA-z-score n = 82 -0.64 ± 1.39 -5.03 to 2.88 2 17
Mid-arm circumference-BA-z-score n = 49 -0.54 ± 1.30 -2.86 to 2.50 2 16
Subscapular skinfold-CA-z-score n = 81 0.59 ± 0.83 -1.56 to 2.31 3 0
Subscapular skinfold-BA-z-score n = 48 0.64 ± 0.87 -1.17 to 2.27 4 0
Triceps-CA-z-score n = 81 1.02 ± 0.74 -0.88 to 2.79 11 0
Triceps-BA-z-score n = 49 1.10 ± 0.72 -1.17 to 2.47 8 0
Height-CA-z-score n = 82 -0.30 ± 1.02 -2.74 to 2.34 1 6
Height-BA-z-score n = 49 0.17 ± 1.12 -3.29 to 2.53 4 2
Weight CA-z-score n = 82 -0.17 ± 1.10 -3.49 to 2.20 4 5
Weight BA-z-score n = 49 0.11 ± 0.91 -2.52 to 1.97 0 2
BMI-CA-z-score n = 82 -0.07 ± 1.04 -2.78 to 2.17 4 4
BMI BA-z-score n = 49 0.05 ± 0.86 -2.58 to 2.09 2 2
BA z-score: z score based on bone age; BMI: Body mass index; CA z-score: z score based on chronological age.
Table 3  Significant associations between medications/serum biomarkers and anthropometric parameters [z -scores based on 
chronological age (n  = 82)] - unadjusted analyses
Variable Mid-arm circumference CA-z-scores Subscapular skinfold CA-z-scores Weight CA-z-scores BMI CA-z-scores
Adalimumab 0.901
(0.08, 1.72)2
0.0333
1.09
(0.05, 2.13)
0.04
Azathioprine -0.65
(-1.25, -0.05)
0.033
-0.5
(-0.85, -0.14)
0.006
-0.7
(-1.16, -0.23)
0.004
-0.56
(-1.004, -0.12)
0.014
Methotrexate 0.75
(0.06, 1.43)
0.032
ESR -0.024
(-0.05, -0.002)
0.036
-0.03
(-0.05, -0.02)
0.0003
-0.02
(-0.04, -0.006)
0.009
Hemoglobin 0.19
(0.04, 0.34)
0.015
1Regression coefficient for unadjusted analyses [i.e., one medication or serum biomarker (independent variable) per model and no adjustment for potential 
confounding]; 2(95% confidence interval); 3P-value. BMI: Body mass index; CA z-score: z score based on chronological age; ESR: Erythrocyte sedimentation 
rate.
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these findings represents a lack of efficacy of thiopurines 
(given that anthropometric parameters and skeletal 
maturation reflect nutritional status/disease status) vs 
a direct negative impact of thiopurines in pediatric CD. 
Patients with lower body composition z-scores and lower 
standardized BA results were not selectively placed on 
thiopurines vs another medication such as methotrexate, 
infliximab, or adalimumab as these measurements were 
obtained at the time of the study. 
Adalimumab and methotrexate were positively 
associated (statistically significant) with measurements 
of fat mass [subscapular CA z-scores (adalimumab/
methotrexate)] and BMI CA z-scores (adalimumab). 
While these medications were not statistically signi-
ficantly associated with these outcome BA z-scores 
due to a smaller sample size available for BA analyses, 
the direction of these associations (positive) remained 
unchanged and the effect sizes were similar to only mildly 
decreased compared with the statistically significant 
positive associations between these medications and 
these outcome CA z-scores, supporting a positive 
association between adalimumab and methotrexate with 
these anthropometric parameter BA z-scores. 
Similar to our finding of a positive association 
between the anti-tumor necrosis factor alpha (TNF-α) 
agent, adalimumab, and BMI, Diamanti et al[48] reported 
that weight and BMI improved in children treated with 
infliximab, but not with mesalazine and azathioprine. 
Wiese et al[49] reported a significant increase in BMI with 
infliximab treatment in adult CD. 
In a pediatric CD study, investigators reported specific 
medications were associated with greater increases 
in race- and sex-specific z-scores for both lean mass 
(infliximab) and fat mass (infliximab, glucocorticoid, 
Table 4  Significant associations between medications/serum biomarkers and anthropometric parameters [z -scores based on 
chronological age (n  = 82)] - adjusted analyses
Variable Mid-arm circumference CA-z -scores Subscapular skinfold CA-z -scores Weight CA-z -scores BMI CA-z -scores
Adalimumab 1.021
(0.18, 1.86)2
0.0183
1.17
(0.13, 2.21)
0.029
Azathioprine -0.64
(-1.26, -0.02)
0.045
-0.47
(-0.83, -0.10)
0.014
-0.73
(-1.17, -0.29)
0.002
-0.58
(-1.03, -0.12)
0.013
Methotrexate 0.81
(0.10, 1.53)
0.027
ESR -0.03
(-0.05, -0.01)
0.01
-0.03
(-0.05, -0.004)
0.024
1Regression coefficient for adjusted analyses [i.e., one medication or serum biomarker (independent variable) per model and CA at study visit, sex, CRP, 
albumin, ESR and hemoglobin are included in the model to adjust for potential confounding]; 2(95% confidence interval); 3P-value. BMI: Body mass index; 
CA z-score: z score based on chronological age; CRP: C-reactive protein; ESR: Erythrocyte sedimentation rate.
Table 5  Significant associations between serum biomarkers and anthropometric parameters [z -scores based on bone age (n  = 49)] 
- unadjusted analyses
Variable Mid-arm circumference 
BA-z -scores
Subscapular skinfold 
BA-z -scores
Triceps skinfold 
BA-z -scores
Weight 
BA-z -scores
BMI 
BA-z -scores
WBC -0.191
(-0.36, -0.02)2
0.0293
-0.12
(-0.24, -0.01)
0.04
-0.16
(-0.28, -0.04)
0.008
ESR -0.03
(-0.04, -0.01)
0.003
-0.02
(-0.03, -0.001)
0.037
CRP -0.03
(-0.07, -0.0001)
0.049
-0.06
(-0.10, -0.02)
0.008
Albumin 0.73
(0.28, 1.18)
0.002
IGF-1 BA-z-scores 0.2
(0.01, 0.38)
0.039
1Regression Coefficient for Unadjusted Analyses [i.e., one serum biomarker (independent variable) per model and no adjustment for potential confounding]; 
2(95% confidence interval); 3P-value. BA z-score: z score based on bone age; BMI: Body mass index; WBC: White blood cell; ESR: Erythrocyte sedimentation 
rate; IGF-1: Insulin-like growth factor-1; CRP: C-reactive protein. 
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and methotrexate) relative to height[50]. Similarly, we 
identified a positive association between methotrexate 
and subscapular skinfold CA z-scores. In a CD patient 
cohort, age 5-25 years, Sentongo et al[14] reported triceps 
skinfold z-scores, also a measure of adiposity, were 
significantly correlated with corticosteroid exposure. Our 
findings do not reveal a statistically significant association 
between history of corticosteroid therapy and current 
anthropometric parameters. 
Csontos et al[31] reported baseline BMI increased 
significantly during initiation of adalimumab/infliximab 
therapy in adult IBD, in agreement with our identified 
positive association between adalimumab and BMI. 
They found fat free mass index also increased. They 
found no significant differences between the effects 
of adalimumab and infliximab on body composition, 
whereas we identified significant associations between 
body composition and adalimumab only, not infliximab. 
Notably, fat free mass index and skeletal muscle mass 
index significantly improved only in males. Subramaniam 
et al[51] reported infliximab was associated with significant 
gains in muscle volume that correlated with male sex 
in adult CD[51]. Supporting these sex differences in 
response to infliximab, in a mouse model of pulmonary 
inflammation in which TNF-α was over expressed in 
mouse lungs, lower body and muscle mass were evident 
only in males[52]. 
Our study does not reveal a sex difference in the 
association between medications and body composition, 
but does identify a statistically significant positive 
association between infliximab and height CA z-scores in 
females only. A positive relationship between infliximab 
and height BA z-scores was also identified in females 
only, but did not reach statistical significance, likely due 
to the smaller sample size available for BA analyses (n 
= 17 females for BA analyses vs n = 35 females for CA 
analyses). The combination of findings described here 
between infliximab and height z-scores (based on CA 
and BA) supports a possible sex difference in response 
to infliximab from the standpoint of statural growth. 
Taken together, these findings of sex differences in 
response to infliximab add to the growing body of 
literature indicating that there may be sex differences 
in the molecular pathways affecting statural growth and 
body composition in CD. Our findings in combination 
with the existing literature raise an intriguing question: 
does TNF-α play an important role in compromising 
body composition in CD males but statural growth in 
females, and if so, why? Tang et al[52] speculated that 
estrogen has protective effects against the actions 
of TNF-α. Ordas et al[53] reported that clearance of 
monoclonal antibodies is higher in men. Ternant et al[54] 
theorized that the central volume of distribution may be 
higher in men because for a given body weight, plasma 
volume is lower in women. 
We found hemoglobin was positively associated, while 
platelets, ESR, and CRP were negatively associated, 
with height CA z-scores in males only, supporting our 
previously reported findings of a greater detrimental 
effect of inflammation on statural growth in males[10]. 
Several investigators have documented that growth 
impairment is more frequent in males[9,10,14,21,32-35]. 
Perhaps the molecular pathways that lead to growth 
impairment in males are different than in females, and 
less responsive to currently used medications, such 
as infliximab. As expected, albumin and IGF-1 BA 
z-scores were positively associated, while ESR and CRP 
were negatively associated with height BA z-scores. In 
contrast, no treatment (5-aminosalicylate, corticosteroids, 
immunomodulators, infliximab, nutritional therapy, 
Table 6  Significant associations between medications/serum biomarkers and height z -scores by sex (based on chronological age 
(female n  = 35; male n  = 47)) - unadjusted analyses
Variable Height CA z -scores Point estimate1 95%CI P  value
Infliximab Females 0.65 0.04, 1.25 0.038
CRP Males -0.04 -0.079, -0.002 0.039
ESR Males -0.03 -0.051, -0.011 0.003
Hemoglobin Males 0.23 0.04, 0.42 0.018
Platelets Males -0.004 -0.006, -0.001 0.005
1Regression coefficient for unadjusted analyses [i.e., one medication or serum biomarker (independent variable) per model and no adjustment for potential 
confounding]. CA z-score: z score based on chronological age; CRP: C-reactive protein; ESR: Erythrocyte sedimentation rate.
Variable Height BA-z -scores Point estimate1 95%CI P  value
Albumin Males and females 0.8 0.22, 1.36 0.008
CRP Males and females -0.06 -0.11, -0.006 0.03
ESR Males and females -0.02 -0.05, -0.003 0.029
IGF-1 BA-z-scores Males and females 0.26 0.03, 0.48 0.025
Table 7  Significant associations between serum biomarkers and height z -scores [based on bone age (n  = 49)] - unadjusted analyses
1Regression coefficient for unadjusted analyses [i.e., one serum biomarker (independent variable) per model and no adjustment for potential confounding]. 
BA z-score: z score based on bone age; BMI: Body mass index; ESR: Erythrocyte sedimentation rate; IGF-1: Insulin-like growth factor-1; CRP: C-reactive 
protein.
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surgical resection) was associated with height, weight 
or BMI at maximal follow up in a pediatric CD cohort in 
Northern France[21]. 
The relationships between medications and anth-
ropometric parameters may reflect efficacy of medi-
cations, side effects of medications, or confounding 
by indication. Since body composition measurements 
were obtained as part of a study protocol and not 
standard of care, it is unlikely these relationships reflect 
confounding by indication since these body composition 
measurements were not available to the care provider. 
Our results suggest methotrexate, infliximab and 
adalimumab are more effective than thiopurines for 
treating pediatric CD. 
As expected, body composition BA z-scores were 
systematically higher than corresponding body com-
position CA z-scores. Patients did not exhibit severe 
deficiencies in fat stores, as reflected by standardized 
subscapular and triceps skinfold measurements. 
Depending on the measurement obtained, 3% to 11% 
had subscapular or triceps skinfold measurement CA 
z-scores or BA z-scores > 2.0, reflecting excess fat 
stores. In contrast, 16%-17% had deficiencies in lean 
mass tissue as reflected by mid-arm circumference 
z-score measurements < -2.0 and only 2% with mid-
arm circumference z-score measurements > 2.0. We 
identified a negative association between thiopurines 
and mid-arm circumference CA z-scores. The published 
literature surrounding the relationship between me-
dications and lean mass tissue is conflicting[31,50-51]. 
More studies are needed to identify the most effective 
treatments for improving lean mass tissue in pediatric 
CD.
Correlations between inflammatory markers/disease 
activity indices and anthropometric parameters have 
been reported by other investigators[5,14,50,55,56], similar 
to our findings. Enhancing our understanding of the 
specific inflammatory cytokines involved in molecular 
pathways affecting body composition and growth is 
critical for optimizing treatment.
Limitations
The etiology of compromised nutritional status/disease 
status is multifactorial. The cross-sectional study design 
does not permit longitudinal assessment of changes in 
anthropometric parameters with respect to medication 
treatment and serum biomarkers to be determined. 
Within-subjects characterization of the influence of 
disease activity and hormone levels on changes in 
anthropometric parameters may clarify the effects of 
long-term inflammation on nutritional status/disease 
status. Nevertheless, our results suggest a mechanistic 
relationship between medications, inflammation and 
anthropometric status/disease status, as well as a 
difference by sex. Prospective longitudinal study, 
collecting additional markers of disease activity/disease 
status such as fecal calprotectin, cross-sectional imaging 
and endoscopic assessment, is required as a next step 
to further investigate these intriguing findings and 
would allow further risk stratification which will improve 
patient counseling, guide expectations, and facilitate an 
individualized treatment approach. Future studies should 
examine the impact of monotherapy vs combination 
therapy (including duration of treatment and drug levels) 
on anthropometric status/disease status.
Summary and Conclusions
Complex processes regulate body composition and 
growth in pediatric CD. We examined the relationship 
between medication treatments and serum inflam-
matory and hormonal biomarkers with anthropometric 
parameters in a well-characterized pediatric CD cohort. 
Our findings reinforce the importance of accounting 
for BA when interpreting anthropometric parameters 
in pediatric CD. The main findings of our study raise 
intriguing questions. 
Thiopurines were negatively associated with specific 
anthropometric parameters. Do thiopurines have a 
negative effect on nutritional status/disease status? 
Alternatively, is the efficacy of thiopurines suboptimal? 
This interesting finding may have significant impli-
cations for pediatric CD treatment and requires further 
investigation in a prospective longitudinal study to 
determine if thiopurines should continue to be utilized as 
a treatment for pediatric CD.
Infliximab was positively associated with standardized 
height in females only. Is there a sex difference in 
response to infliximab from the standpoint of statural 
growth? Specific serum biomarkers were associated 
with standardized height in males only, supporting the 
hypothesis that inflammation has a more detrimental 
effect on statural growth in males. The combination of 
these findings lends further support to the theory that 
sex differences in the molecular pathways driving statural 
growth impairment in pediatric CD exist and should be 
delineated in a prospective longitudinal study utilizing 
height velocity BA z-scores as the primary outcome. 
An improved understanding of this sex difference in 
response to treatment would be a huge step towards 
enhancing risk prediction and individualized treatment.
The studies presented herein contribute to a better 
understanding of the relationship between medications 
and serum inflammatory and hormonal biomarkers 
with anthropometric parameters in pediatric CD. These 
findings serve as a foundation on which to build future 
studies with the goal of identifying patients at highest 
risk for poor outcomes, enhancing treatment algorithms, 
and ultimately developing individual treatment 
approaches based on risk stratification. The present 
study may provide a basis for mechanistic studies in 
many pediatric chronic inflammatory conditions.
ARTICLE HIGHLIGHTS
Research background
Similar to impaired statural growth (height velocity), a dynamic marker of 
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disease status, body composition deficits may reflect poorly controlled disease 
despite the absence of overt clinical intestinal symptoms. Delayed bone age 
(BA) is common in pediatric Crohn’s disease (CD). Determination of BA allows 
clinically meaningful interpretation of growth in the context of skeletal maturity 
in pediatric CD. The impact of accounting for BA in the interpretation of body 
composition is unclear. Accurate interpretation of body composition is important 
since it reflects nutritional and disease status. Not only is nutritional status 
an important determinant of pubertal development and growth velocity, it is a 
prognostic factor for disease course. The association between medications 
and serum inflammatory and hormonal biomarkers with anthropometric 
measurements is not well delineated in pediatric CD, particularly after adjusting 
for maturational status (BA).
Research motivation
Nutritional status is an important factor to consider when making therapeutic 
decisions given its association with poor outcomes. Yet, the impact of 
treatments on anthropometric measurements is poorly defined and has not 
received sufficient attention. 
Research objectives 
Our aims were to determine the distribution of anthropometric parameters 
based on CA (CA z-scores) and BA (BA z-scores) and characterize the 
associations between medications and serum biomarkers with anthropometric 
parameter z-scores in pediatric CD.
Research methods
CD patients [< chronological age (CA) 21 years] were prospectively enrolled in 
a cross-sectional study. Descriptive statistics were generated for participants’ 
demographic characteristics and key variables of interest. Paired t-tests were 
used to compare anthropometric parameter z-scores calculated based on 
CA (CA z-scores) and BA (BA z-scores) for interpretation of anthropometric 
parameters. Linear regression was utilized to examine associations between 
medications and serum biomarkers with anthropometric parameter z-scores 
calculated based on CA (n = 82) and BA (n = 49). We reported regression 
coefficients as well as their corresponding p-values and 95% confidence 
intervals.
Research results
Mean CA at the time of the study visit was 15.3 ± 3.5 (standard deviation; range 
= 4.8-20.7) years. Mean triceps skinfold, subscapular skinfold and mid-arm 
circumference (MAC) BA z-scores were higher than corresponding CA z-scores. 
Medications were positively associated with subscapular skinfold (adalimumab 
and methotrexate) and BMI (adalimumab) CA z-scores. Azathioprine/6-
mercaptopurine were negatively associated with MAC, subscapular skinfold, 
weight and BMI CA z-scores . ESR, CRP, and WBC count were negatively 
associated, while albumin and IGF-1 BA z-scores were positively associated 
with specific AP z-scores. Mean height CA z-scores were higher in females, 
not males, treated with infliximab. Hemoglobin was positively associated, while 
platelets, ESR and CRP were negatively associated with height CA z-scores in 
males, not females.
Research conclusions
Our findings reinforce the importance of accounting for BA when interpreting 
anthropometric parameters in pediatric CD. The main findings of our study 
raise intriguing questions. Thiopurines were negatively associated with specific 
anthropometric parameters. Do thiopurines have a negative effect on nutritional 
status/disease status? Alternatively, is the efficacy of thiopurines suboptimal? 
Infliximab was positively associated with standardized height in females only. Is 
there a sex difference in response to infliximab from the standpoint of statural 
growth? Specific serum biomarkers were associated with standardized height in 
males only, supporting the hypothesis that inflammation has a more detrimental 
effect on statural growth in males. Our results suggest a mechanistic 
relationship between medications, inflammation and anthropometric status/
disease status, as well as a difference by sex. The studies presented herein 
contribute to a better understanding of the relationship between medications 
and serum inflammatory and hormonal biomarkers with anthropometric 
parameters in pediatric CD. Prospective longitudinal study is required as a next 
step to further investigate these intriguing findings and would allow further risk 
stratification which will improve patient counseling, guide expectations, and 
facilitate an individualized treatment approach. 
Research perspectives
These findings serve as a foundation on which to build future studies with 
the goal of identifying patients at highest risk for poor outcomes, enhancing 
treatment algorithms, and ultimately developing individual treatment 
approaches based on risk stratification. The present study may provide a basis 
for mechanistic studies in many pediatric chronic inflammatory conditions.
ACKNOWLEDGMENTS
We thank the patients for participating in this study. We 
thank Dr. Keith C Mages, Clinical Medical Librarian at 
the Samuel J Wood Library, Weill Cornell Medicine, for 
library services.
REFERENCES
1 Burnham JM, Shults J, Semeao E, Foster B, Zemel BS, Stallings 
VA, Leonard MB. Whole body BMC in pediatric Crohn disease: 
independent effects of altered growth, maturation, and body 
composition. J Bone Miner Res 2004; 19: 1961-1968 [PMID: 
15537438 DOI: 10.1359/JBMR.040908]
2 Burnham JM, Shults J, Semeao E, Foster BJ, Zemel BS, Stallings 
VA, Leonard MB. Body-composition alterations consistent with 
cachexia in children and young adults with Crohn disease. Am J 
Clin Nutr 2005; 82: 413-420 [PMID: 16087987 DOI: 10.1093/
ajcn/82.2.413]
3 Boot AM, Bouquet J, Krenning EP, de Muinck Keizer-Schrama 
SM. Bone mineral density and nutritional status in children with 
chronic inflammatory bowel disease. Gut 1998; 42: 188-194 
[PMID: 9536942 DOI: 10.1136/gut.42.2.188]
4 Jahnsen J, Falch JA, Mowinckel P, Aadland E. Body composition 
in patients with inflammatory bowel disease: a population-based 
study. Am J Gastroenterol 2003; 98: 1556-1562 [PMID: 12873577 
DOI: 10.1111/j.1572-0241.2003.07520.x]
5 Thayu M, Shults J, Burnham JM, Zemel BS, Baldassano RN, 
Leonard MB. Gender differences in body composition deficits 
at diagnosis in children and adolescents with Crohn’s disease. 
Inflamm Bowel Dis 2007; 13: 1121-1128 [PMID: 17427245 DOI: 
10.1002/ibd.20149]
6 Sylvester FA, Leopold S, Lincoln M, Hyams JS, Griffiths AM, 
Lerer T. A two-year longitudinal study of persistent lean tissue 
deficits in children with Crohn’s disease. Clin Gastroenterol 
Hepatol 2009; 7: 452-455 [PMID: 19249399 DOI: 10.1016/
j.cgh.2008.12.017]
7 Sousa Guerreiro C, Cravo M, Costa AR, Miranda A, Tavares 
L, Moura-Santos P, MarquesVidal P, Nobre Leitão C. A 
comprehensive approach to evaluate nutritional status in Crohn’
s patients in the era of biologic therapy: a case-control study. Am 
J Gastroenterol 2007; 102: 2551-2556 [PMID: 17680845 DOI: 
10.1111/j.1572-0241.2007.01439.x]
8 Kugathasan S, Nebel J, Skelton JA, Markowitz J, Keljo D, 
Rosh J, LeLeiko N, Mack D, Griffiths A, Bousvaros A, Evans J, 
Mezoff A, Moyer S, Oliva-Hemker M, Otley A, Pfefferkorn M, 
Crandall W, Wyllie R, Hyams J; Wisconsin Pediatric Inflammatory 
Bowel Disease Alliance; Pediatric Inflammatory Bowel Disease 
Collaborative Research Group. Body mass index in children 
with newly diagnosed inflammatory bowel disease: observations 
from two multicenter North American inception cohorts. J 
Pediatr 2007; 151: 523-527 [PMID: 17961699 DOI: 10.1016/
j.jpeds.2007.04.004]
9 Gupta N, Bostrom AG, Kirschner BS, Ferry GD, Winter HS, 
Baldassano RN, Gold BD, Abramson O, Smith T, Cohen SA, 
Heyman MB. Gender differences in presentation and course 
of disease in pediatric patients with Crohn disease. Pediatrics 
2007; 120: e1418-e1425 [PMID: 18055660 DOI: 10.1542/
Gupta N et al . Anthropometrics in pediatric CD
2045 May 14, 2018|Volume 24|Issue 18|WJG|www.wjgnet.com
peds.2007-0905]
10 Gupta N, Lustig RH, Kohn MA, McCracken M, Vittinghoff E. 
Sex differences in statural growth impairment in Crohn’s disease: 
role of IGF-1. Inflamm Bowel Dis 2011; 17: 2318-2325 [PMID: 
21287667 DOI: 10.1002/ibd.21617]
11 Gupta N, Lustig RH, Kohn MA, Vittinghoff E. Determination of 
bone age in pediatric patients with Crohn’s disease should become 
part of routine care. Inflamm Bowel Dis 2013; 19: 61-65 [PMID: 
22552908 DOI: 10.1002/ibd.22979]
12 Motil KJ, Grand RJ, Davis-Kraft L, Ferlic LL, Smith EO. Growth 
failure in children with inflammatory bowel disease: a prospective 
study. Gastroenterology 1993; 105: 681-691 [PMID: 8359640 
DOI: 10.1016/0016-5085(93)90883-E]
13 Hill RJ, Brookes DS, Lewindon PJ, Withers GD, Ee LC, Connor 
FL, Cleghorn GJ, Davies PS. Bone health in children with 
inflammatory bowel disease: adjusting for bone age. J Pediatr 
Gastroenterol Nutr 2009; 48: 538-543 [PMID: 19367176 DOI: 
10.1097/MPG.0b013e31818cb4b6]
14 Sentongo TA, Semeao EJ, Piccoli DA, Stallings VA, Zemel BS. 
Growth, body composition, and nutritional status in children and 
adolescents with Crohn’s disease. J Pediatr Gastroenterol Nutr 
2000; 31: 33-40 [PMID: 10896068 DOI: 10.1097/00005176-20000
7000-00009]
15 McCaffery TD, Nasr K, Lawrence AM, Kirsner JB. Severe growth 
retardation in children with inflammatory bowel disease. Pediatrics 
1970; 45: 386-393 [PMID: 4315271]
16 Savage MO, Beattie RM, Camacho-Hübner C, Walker-Smith 
JA, Sanderson IR. Growth in Crohn’s disease. Acta Paediatr 
Suppl 1999; 88: 89-92 [PMID: 10102061 DOI: 10.1111/
j.1651-2227.1999.tb14360.x]
17 Greulich WW,  Pyle SI. Radiographic Atlas of Skeletal 
Development of the Hand and Wrist, 2nd ed. Stanford, CA: Stanford 
University Press 1959 [DOI: 10.1017/S1120962300018680]
18 Jones G, Ma D. Skeletal age deviation assessed by the Tanner-
Whitehouse 2 method is associated with bone mass and fracture 
risk in children. Bone 2005; 36: 352-357 [PMID: 15780962 DOI: 
10.1016/j.bone.2004.11.001]
19 Johnson W, Stovitz SD, Choh AC, Czerwinski SA, Towne B, 
Demerath EW. Patterns of linear growth and skeletal maturation 
from birth to 18 years of age in overweight young adults. Int J 
Obes (Lond) 2012; 36: 535-541 [PMID: 22124455 DOI: 10.1038/
ijo.2011.238]
20 Forbes A, Escher J, Hébuterne X, Kłęk S, Krznaric Z, Schneider 
S, Shamir R, Stardelova K, Wierdsma N, Wiskin AE, Bischoff 
SC. ESPEN guideline: Clinical nutrition in inflammatory bowel 
disease. Clin Nutr 2017; 36: 321-347 [PMID: 28131521 DOI: 
10.1016/j.clnu.2016.12.027]
21 Vasseur F, Gower-Rousseau C, Vernier-Massouille G, Dupas JL, 
Merle V, Merlin B, Lerebours E, Savoye G, Salomez JL, Cortot A, 
Colombel JF, Turck D. Nutritional status and growth in pediatric 
Crohn’s disease: a population-based study. Am J Gastroenterol 
2010; 105: 1893-1900 [PMID: 20145606 DOI: 10.1038/
ajg.2010.20]
22 Ananthakrishnan AN ,  McGinley EL. Infection-related 
hospitalizations are associated with increased mortality in patients 
with inflammatory bowel diseases. J Crohns Colitis 2013; 7: 
107-112 [PMID: 22440891 DOI: 10.1016/j.crohns.2012.02.015]
23 Nguyen GC, Munsell M, Harris ML. Nationwide prevalence and 
prognostic significance of clinically diagnosable protein-calorie 
malnutrition in hospitalized inflammatory bowel disease patients. 
Inflamm Bowel Dis 2008; 14: 1105-1111 [PMID: 18302272 DOI: 
10.1002/ibd.20429]
24 Ananthakrishnan AN, McGinley EL, Binion DG, Saeian 
K. A novel risk score to stratify severity of Crohn’s disease 
hospitalizations. Am J Gastroenterol 2010; 105: 1799-1807 [PMID: 
20216534 DOI: 10.1038/ajg.2010.105]
25 Gajendran M, Umapathy C, Loganathan P, Hashash JG, 
Koutroubakis IE, Binion DG. Analysis of Hospital-Based 
Emergency Department Visits for Inflammatory Bowel Disease in 
the USA. Dig Dis Sci 2016; 61: 389-399 [PMID: 26423080 DOI: 
10.1007/s10620-015-3895-2]
26 Wallaert JB, De Martino RR, Marsicovetere PS, Goodney PP, 
Finlayson SR, Murray JJ, Holubar SD. Venous thromboembolism 
after surgery for inflammatory bowel disease: are there 
modifiable risk factors? Data from ACS NSQIP. Dis Colon 
Rectum 2012; 55: 1138-1144 [PMID: 23044674 DOI: 10.1097/
DCR.0b013e3182698f60]
27 Nguyen DL, Parekh N, Bechtold ML, Jamal MM. National Trends 
and In-Hospital Outcomes of Adult Patients With Inflammatory 
Bowel Disease Receiving Parenteral Nutrition Support. JPEN J 
Parenter Enteral Nutr 2016; 40: 412-416 [PMID: 24687967 DOI: 
10.1177/0148607114528715]
28 Addolorato G, Capristo E, Stefanini GF, Gasbarrini G. 
Inflammatory bowel disease: a study of the association between 
anxiety and depression, physical morbidity, and nutritional status. 
Scand J Gastroenterol 1997; 32: 1013-1021 [PMID: 9361174 DOI: 
10.3109/00365529709011218]
29 Forbes GB. Perspectives on body composition. Curr Opin Clin 
Nutr Metab Care 2002; 5: 25-30 [PMID: 11790945 DOI: 10.1097/
00075197-200201000-00005]
30 Thangarajah D, Hyde MJ, Konteti VK, Santhakumaran S, Frost 
G, Fell JM. Systematic review: Body composition in children with 
inflammatory bowel disease. Aliment Pharmacol Ther 2015; 42: 
142-157 [PMID: 26043941 DOI: 10.1111/apt.13218]
31 Csontos ÁA, Molnár A, Piri Z, Katona B, Dakó S, Pálfi E, 
Miheller P. The Effect of anti-TNFα Induction Therapy on the 
Nutritional Status and Dietary Intake in Inflammatory Bowel 
Disease. J Gastrointestin Liver Dis 2016; 25: 49-56 [PMID: 
27014753 DOI: 10.15403/jgld.2014.1121.251.tnf]
32 Gupta N. Summary of “Growth and nutritional status in pediatric 
Crohn’s disease” with a focus on sex differences in statural growth 
impairment. J Pediatr Gastroenterol Nutr 2011; 53: 227-228 
[PMID: 21788770 DOI: 10.1097/MPG.0b013e31821d37dc]
33 Griffiths AM, Nguyen P, Smith C, MacMillan JH, Sherman PM. 
Growth and clinical course of children with Crohn’s disease. Gut 
1993; 34: 939-943 [PMID: 8344582 DOI: 10.1136/gut.34.7.939]
34 Pigneur B, Seksik P, Viola S, Viala J, Beaugerie L, Girardet JP, 
Ruemmele FM, Cosnes J. Natural history of Crohn’s disease: 
comparison between childhood- and adult-onset disease. Inflamm 
Bowel Dis 2010; 16: 953-961 [PMID: 19834970 DOI: 10.1002/
ibd.21152]
35 Mason A, Malik S, McMillan M, McNeilly JD, Bishop J, 
McGrogan P, Russell RK, Ahmed SF. A prospective longitudinal 
study of growth and pubertal progress in adolescents with 
inflammatory bowel disease. Horm Res Paediatr 2015; 83: 45-54 
[PMID: 25531796 DOI: 10.1159/000369457]
36 Gupta N, Lustig RH, Kohn MA, Vittinghoff E. Menarche in 
pediatric patients with Crohn’s disease. Dig Dis Sci 2012; 57: 
2975-2981 [PMID: 22744430 DOI: 10.1007/s10620-012-2235-z]
37 Centers for Disease Control and Prevention. National Health 
and Nutrition Examination Survey (NHANES) Anthropometry 
Manual. Available from: URL: https://www.cdc.gov/nchs/data/
nhanes/nhanes_11_12/Anthropometry_Procedures_Manual.pdf
38 Morris NM, Udry JR. Validation of a self-administered instrument 
to assess stage of adolescent development. J Youth Adolesc 1980; 9: 
271-280 [PMID: 24318082 DOI: 10.1007/BF02088471]
39 Smith DW. Growth and its disorders: basics and standards, 
approach and classifications, growth deficiency disorders, growth 
excess disorders, obesity. Major Probl Clin Pediatr 1977; 15: 1-155 
[PMID: 190484]
40 McDowell MA, Fryar CD, Ogden CL, Flegal KM. Anthropometric 
reference data for children and adults: United States, 2003–2006. 
Natl Health Stat Report 2008; 10: 1-48 [PMID: 25585443 DOI: 
10.1037/e623932009-001]
41 McDowell MA, Fryar CD, Hirsch R, Ogden CL. Anthropometric 
reference data for children and adults: U.S. population, 1999-2002. 
Adv Data 2005; 361: 1-5 [PMID: 16018338]
42 Frisancho AR. New norms of upper limb fat and muscle areas 
for assessment of nutritional status. Am J Clin Nutr 1981; 34: 
2540-2545 [PMID: 6975564 DOI: 10.1093/ajcn/34.11.2540]
Gupta N et al . Anthropometrics in pediatric CD
2046 May 14, 2018|Volume 24|Issue 18|WJG|www.wjgnet.com
43 Tanner JM, Whitehouse RH. Revised standards for triceps and 
subscapular skinfolds in British children. Arch Dis Child 1975; 50: 
142-145 [PMID: 1130819 DOI: 10.1136/adc.50.2.142]
44 Davies PS, Day JM, Cole TJ. Converting Tanner-Whitehouse 
reference tricep and subscapular skinfold measurements to standard 
deviation scores. Eur J Clin Nutr 1993; 47: 559-566 [PMID: 
8404792]
45 Centers for Disease Control and Prevention. CDC Growth 
Charts: Percentile Data Files with LMS Values. Available from: 
URL: https://www.cdc.gov/growthcharts/percentile_data_files.htm
46 Markowitz J, Grancher K, Kohn N, Lesser M, Daum F. A 
multicenter trial of 6-mercaptopurine and prednisone in children 
with newly diagnosed Crohn’s disease. Gastroenterology 2000; 
119: 895-902 [PMID: 11040176 DOI: 10.1053/gast.2000.18144]
47 Hyams JS, Dubinsky MC, Baldassano RN, Colletti RB, Cucchiara 
S, Escher J, Faubion W, Fell J, Gold BD, Griffiths A, Koletzko S, 
Kugathasan S, Markowitz J, Ruemmele FM, Veereman G, Winter 
H, Masel N, Shin CR, Tang KL, Thayu M. Infliximab Is Not 
Associated With Increased Risk of Malignancy or Hemophagocytic 
Lymphohistiocytosis in Pediatric Patients With Inflammatory 
Bowel Disease. Gastroenterology 2017; 152: 1901-1914.e3 [PMID: 
28193515 DOI: 10.1053/j.gastro.2017.02.004]
48 Diamanti A, Basso MS, Gambarara M, Papadatou B, Bracci F, 
Noto C, Castro M. Positive impact of blocking tumor necrosis 
factor alpha on the nutritional status in pediatric Crohn’s disease 
patients. Int J Colorectal Dis 2009; 24: 19-25 [PMID: 18797887 
DOI: 10.1007/s00384-008-0578-x]
49 Wiese D, Lashner B, Seidner D. Measurement of nutrition status 
in Crohn’s disease patients receiving infliximab therapy. Nutr Clin 
Pract 2008; 23: 551-556 [PMID: 18849561 DOI: 10.1177/088453
3608323421]
50 Thayu M, Denson LA, Shults J, Zemel BS, Burnham JM, 
Baldassano RN, Howard KM, Ryan A, Leonard MB. Determinants 
of changes in linear growth and body composition in incident 
pediatric Crohn’s disease. Gastroenterology 2010; 139: 430-438 
[PMID: 20417635 DOI: 10.1053/j.gastro.2010.04.044]
51 Subramaniam K, Fallon K, Ruut T, Lane D, McKay R, Shadbolt B, 
Ang S, Cook M, Platten J, Pavli P, Taupin D. Infliximab reverses 
inflammatory muscle wasting (sarcopenia) in Crohn’s disease. 
Aliment Pharmacol Ther 2015; 41: 419-428 [PMID: 25580985 
DOI: 10.1111/apt.13058]
52 Tang K, Murano G, Wagner H, Nogueira L, Wagner PD, Tang 
A, Dalton ND, Gu Y, Peterson KL, Breen EC. Impaired exercise 
capacity and skeletal muscle function in a mouse model of pulmonary 
inflammation. J Appl Physiol (1985) 2013; 114: 1340-1350 [PMID: 
23449936 DOI: 10.1152/japplphysiol.00607.2012]
53 Ordás I ,  Mould DR, Feagan BG, Sandborn WJ. Anti-
TNF monoclonal antibodies in inflammatory bowel disease: 
pharmacokinetics-based dosing paradigms. Clin Pharmacol Ther 
2012; 91: 635-646 [PMID: 22357456 DOI: 10.1038/clpt.2011.328]
54 Ternant D, Aubourg A, Magdelaine-Beuzelin C, Degenne D, 
Watier H, Picon L, Paintaud G. Infliximab pharmacokinetics in 
inflammatory bowel disease patients. Ther Drug Monit 2008; 30: 
523-529 [PMID: 18641542 DOI: 10.1097/FTD.0b013e318180e300]
55 Schneider SM, Al-Jaouni R, Filippi J, Wiroth JB, Zeanandin G, 
Arab K, Hébuterne X. Sarcopenia is prevalent in patients with 
Crohn’s disease in clinical remission. Inflamm Bowel Dis 2008; 14: 
1562-1568 [PMID: 18478564 DOI: 10.1002/ibd.20504]
56 Reimund JM, Arondel Y, Escalin G, Finck G, Baumann R, Duclos 
B. Immune activation and nutritional status in adult Crohn’s disease 
patients. Dig Liver Dis 2005; 37: 424-431 [PMID: 15893281 DOI: 
10.1016/j.dld.2005.01.010]
P- Reviewer: Gazouli M, Nielsen OH, Vasudevan A    S- Editor: Ma YJ 
L- Editor: A    E- Editor: Huang Y
Gupta N et al . Anthropometrics in pediatric CD
                                      © 2018 Baishideng Publishing Group Inc. All rights reserved.
Published by Baishideng Publishing Group Inc
7901 Stoneridge Drive, Suite 501, Pleasanton, CA 94588, USA
Telephone: +1-925-223-8242
Fax: +1-925-223-8243
E-mail: bpgoffice@wjgnet.com
Help Desk: http://www.f6publishing.com/helpdesk
http://www.wjgnet.com
I S S N  1 0  0 7  -   9  3 2  7
9    7 7 1 0  07   9 3 2 0 45
1  8
